RAYALDEE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rayaldee, and what generic alternatives are available?
Rayaldee is a drug marketed by Eirgen and is included in one NDA. There are sixteen patents protecting this drug.
This drug has one hundred and seventy-two patent family members in thirty-six countries.
The generic ingredient in RAYALDEE is calcifediol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the calcifediol profile page.
DrugPatentWatch® Generic Entry Outlook for Rayaldee
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RAYALDEE?
- What are the global sales for RAYALDEE?
- What is Average Wholesale Price for RAYALDEE?
Summary for RAYALDEE
| International Patents: | 172 |
| US Patents: | 16 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,119 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RAYALDEE |
| What excipients (inactive ingredients) are in RAYALDEE? | RAYALDEE excipients list |
| DailyMed Link: | RAYALDEE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RAYALDEE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RAYALDEE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| OPKO Health, Inc. | Phase 2 |
Pharmacology for RAYALDEE
| Drug Class | Vitamin D3 Analog |
US Patents and Regulatory Information for RAYALDEE
RAYALDEE is protected by twenty-two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RAYALDEE is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting RAYALDEE
Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stabilized modified release vitamin D formulation and method of administering same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stabilized modified release vitamin D formulation and method of administering same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods for controlled release oral dosage of a vitamin D compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3 OR 4 CKD WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING CHOLESTYRAMINE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING PHENOBARBITAL OR OTHER ANTICONVULSANTS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING CYP3A INHIBITORS
Method for treating secondary hyperparathyroidism in CKD
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D
Methods and compositions for controlled release oral dosage of a vitamin D compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY
Methods for controlled release oral dosage of a vitamin D compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE
Oral dosage form of 25-hydroxyvitamin D
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Method for treating secondary hyperparathyroidism in CKD
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE
Method for controlled release oral dosage of a vitamin D compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF SUSTAINED OR EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR 4
Stabilized modified release vitamin D formulation and method of administering same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Method for treating secondary hyperparathyroidism in CKD
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
Method for treating secondary hyperparathyroidism in CKD
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS
Method for treating secondary hyperparathyroidism in CKD
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
Method for treating secondary hyperparathyroidism in CKD
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
Method for treating secondary hyperparathyroidism in CKD
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eirgen | RAYALDEE | calcifediol | CAPSULE, EXTENDED RELEASE;ORAL | 208010-001 | Jun 17, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eirgen | RAYALDEE | calcifediol | CAPSULE, EXTENDED RELEASE;ORAL | 208010-001 | Jun 17, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Eirgen | RAYALDEE | calcifediol | CAPSULE, EXTENDED RELEASE;ORAL | 208010-001 | Jun 17, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Eirgen | RAYALDEE | calcifediol | CAPSULE, EXTENDED RELEASE;ORAL | 208010-001 | Jun 17, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Eirgen | RAYALDEE | calcifediol | CAPSULE, EXTENDED RELEASE;ORAL | 208010-001 | Jun 17, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eirgen | RAYALDEE | calcifediol | CAPSULE, EXTENDED RELEASE;ORAL | 208010-001 | Jun 17, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RAYALDEE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eirgen | RAYALDEE | calcifediol | CAPSULE, EXTENDED RELEASE;ORAL | 208010-001 | Jun 17, 2016 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RAYALDEE
When does loss-of-exclusivity occur for RAYALDEE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 5576
Patent: FORMULACIÓN DE VITAMINA D DE LIBERACIÓN MODIFICADA ESTABILIZADA Y MÉTODO PARA ADMINISTRARLA
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 14228069
Patent: Stabilized modified release vitamin D formulation and method of administring same
Estimated Expiration: ⤷ Sign Up
Patent: 19200268
Patent: STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2015023658
Patent: formulação de vitamina d de liberação modificada, estabilizada e método de administração desta
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 05409
Patent: FORMULATION DE VITAMINE D A LIBERATION MODIFIEE STABILISEE ET SON PROCEDE D'ADMINISTRATION (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 15002659
Patent: Formulación de vitamina d de liberación modificada estabilizada y método de administración de la misma
Estimated Expiration: ⤷ Sign Up
China
Patent: 5246464
Patent: STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTRING SAME
Estimated Expiration: ⤷ Sign Up
Patent: 1346071
Patent: 稳定化修饰释放维生素D制剂和施用其的方法 (Stabilized modified release vitamin D formulation and method of administring same)
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 190178
Patent: FORMULACIÓN DE VITAMINA D DE LIBERACIÓN MODIFICADA Y ESTABILIZADA Y MÉTODO DE ADMINISTRACIÓN DE LA MISMA
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0201284
Estimated Expiration: ⤷ Sign Up
Patent: 0201869
Estimated Expiration: ⤷ Sign Up
Patent: 0211265
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 23167
Estimated Expiration: ⤷ Sign Up
Patent: 23568
Estimated Expiration: ⤷ Sign Up
Patent: 24393
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 68172
Estimated Expiration: ⤷ Sign Up
Patent: 32773
Estimated Expiration: ⤷ Sign Up
Patent: 50016
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 23024864
Patent: FORMULACIÓN DE VITAMINA D DE LIBERACIÓN MODIFICADA Y ESTABILIZADA Y MÉTODO DE ADMINISTRACIÓN DE LA MISMA
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8867
Patent: СТАБИЛИЗИРОВАННЫЙ СОСТАВ ВИТАМИНА D С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION)
Estimated Expiration: ⤷ Sign Up
Patent: 1591809
Patent: СТАБИЛИЗИРОВАННЫЙ СОСТАВ ВИТАМИНА D С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ И СПОСОБ ЕГО ВВЕДЕНИЯ
Estimated Expiration: ⤷ Sign Up
Patent: 1991774
Patent: СТАБИЛИЗИРОВАННЫЙ СОСТАВ ВИТАМИНА D С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ И СПОСОБ ЕГО ВВЕДЕНИЯ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 68172
Patent: FORMULATION DE VITAMINE D À LIBÉRATION MODIFIÉE STABILISÉE ET SON PROCÉDÉ D'ADMINISTRATION (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTRING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 32773
Patent: FORMULATION DE VITAMINE D À LIBÉRATION MODIFIÉE STABILISÉE ET SON PROCÉDÉ D'ADMINISTRATION (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 50016
Patent: FORMULATION DE VITAMINE D À LIBÉRATION MODIFIÉE STABILISÉE ET SON PROCÉDÉ D'ADMINISTRATION (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 88638
Patent: FORMULATION DE VITAMINE D À LIBÉRATION MODIFIÉE STABILISÉE ET SON PROCÉDÉ D'ADMINISTRATION (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME)
Estimated Expiration: ⤷ Sign Up
Germany
Patent: 2014011525
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 20128
Patent: 穩定化修飾釋放維生素 製劑和施用其的方法 (STABILIZED MODIFIED RELEASE VITAMIN FORMULATION AND METHOD OF ADMINISTRING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 20362
Patent: 穩定化修飾釋放維生素 製劑和施用其的方法 (STABILIZED MODIFIED RELEASE VITAMIN FORMULATION AND METHOD OF ADMINISTRING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 56895
Patent: 穩定化修飾的釋放維生素D製劑及其給藥方法 (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 51923
Estimated Expiration: ⤷ Sign Up
Patent: 52014
Estimated Expiration: ⤷ Sign Up
Patent: 55591
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 1456
Patent: פורמולציה מיוצבת ובעלת שחרור מבוקר של ויטמין, d , ושיטות לנתינתה (Stabilized modified release vitamin d formulation and method of administring same)
Estimated Expiration: ⤷ Sign Up
Patent: 4841
Patent: פורמולציה מיוצבת ובעלת שחרור מבוקר של ויטמין d , ושיטות לנתינתה (Stabilized modified release vitamin d formulation and method of administering same)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 92051
Estimated Expiration: ⤷ Sign Up
Patent: 33268
Estimated Expiration: ⤷ Sign Up
Patent: 82832
Estimated Expiration: ⤷ Sign Up
Patent: 16517429
Patent: 安定化調整放出ビタミンＤ製剤及びその投与方法
Estimated Expiration: ⤷ Sign Up
Patent: 18012737
Patent: 安定化調整放出ビタミンＤ製剤及びその投与方法 (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING THE SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 19135264
Patent: 安定化調整放出ビタミンＤ製剤及びその投与方法 (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING THE SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 21155460
Patent: 安定化調整放出ビタミンＤ製剤及びその投与方法 (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING THE SAME)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 68172
Estimated Expiration: ⤷ Sign Up
Patent: 32773
Estimated Expiration: ⤷ Sign Up
Patent: 50016
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 4092
Patent: STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 15012625
Patent: FORMULACION DE VITAMINA D DE LIBERACION MODIFICADA ESTABILIZADA Y METODO PARA ADMINISTRATIVA Y METODO PARA ADMINISTRAR LA MISMA. (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTRING SAME.)
Estimated Expiration: ⤷ Sign Up
Patent: 20011736
Patent: FORMULACION DE VITAMINA D DE LIBERACION MODIFICADA ESTABILIZADA Y METODO PARA ADMINISTRAR LA MISMA. (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTRING SAME.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 1924
Patent: Stabilized modified release vitamin d formulation and method of administering same
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 21007
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 151761
Patent: FORMULACION DE VITAMINA D DE LIBERACION MODIFICADA Y ESTABILIZADA Y METODO DE ADMINISTRACION DE LA MISMA
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 015502162
Patent: STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
Estimated Expiration: ⤷ Sign Up
Patent: 021551127
Patent: STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 68172
Estimated Expiration: ⤷ Sign Up
Patent: 32773
Estimated Expiration: ⤷ Sign Up
Patent: 50016
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 68172
Estimated Expiration: ⤷ Sign Up
Patent: 32773
Estimated Expiration: ⤷ Sign Up
Patent: 50016
Estimated Expiration: ⤷ Sign Up
Saudi Arabia
Patent: 5361134
Patent: صيغة مستقرة ذات إطلاق متحكم فيه لمركب فيتامين د وطريقة إعطائها (Stabilized controlled release formulation of compound vitamin d and method of administering same)
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 846
Patent: STABILIZOVANA FORMULACIJA VITAMINA D SA MODIFIKOVANIM OSLOBAĐANJEM I POSTUPAK ZA DAVANJE ISTE (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTRING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 132
Patent: STABILIZOVANA FORMULACIJA VITAMINA D SA MODIFIKOVANIM OSLOBAĐANJEM I POSTUPAK ZA NJENU PRIMENU (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 176
Patent: STABILIZOVANA FORMULACIJA VITAMINA D SA MODIFIKOVANIM OSLOBAĐANJEM I POSTUPAK ZA NJENU PRIMENU (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201703517V
Patent: STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
Estimated Expiration: ⤷ Sign Up
Patent: 201507323P
Patent: STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTRING SAME
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 68172
Estimated Expiration: ⤷ Sign Up
Patent: 32773
Estimated Expiration: ⤷ Sign Up
Patent: 50016
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1847947
Estimated Expiration: ⤷ Sign Up
Patent: 2203003
Estimated Expiration: ⤷ Sign Up
Patent: 140113374
Patent: STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
Estimated Expiration: ⤷ Sign Up
Patent: 140140004
Patent: STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
Estimated Expiration: ⤷ Sign Up
Patent: 190095216
Patent: 안정화되고 변형된 비타민 Ｄ 방출 제형 및 이의 투여 방법 (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME)
Estimated Expiration: ⤷ Sign Up
Patent: 210078463
Patent: 안정화되고 변형된 비타민 Ｄ 방출 제형 및 이의 투여 방법 (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 09477
Estimated Expiration: ⤷ Sign Up
Patent: 34900
Estimated Expiration: ⤷ Sign Up
Patent: 82567
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 59753
Estimated Expiration: ⤷ Sign Up
Patent: 1707689
Patent: Stabilized modified release vitamin D formulation and method of administering same
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 3386
Patent: СТАБІЛІЗОВАНИЙ СКЛАД ВІТАМІНУ D ІЗ МОДИФІКОВАНИМ ВИВІЛЬНЕННЯМ І СПОСІБ ЙОГО ВВЕДЕННЯ (STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTRING SAME)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering RAYALDEE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Taiwan | I659753 | ⤷ Sign Up | |
| Denmark | 3650016 | ⤷ Sign Up | |
| Germany | 60031825 | ⤷ Sign Up | |
| Austria | 345113 | ⤷ Sign Up | |
| Portugal | 2148661 | ⤷ Sign Up | |
| Japan | 5501956 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RAYALDEE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2968172 | 122021000009 | Germany | ⤷ Sign Up | PRODUCT NAME: CALCIFEDIOL UND/ODER PHARMAZEUTISCH AKZEPTABLE SALZE UND HYDRATE DAVON, BEVORZUGT CALCIFEDIOLMONOHYDRAT; REGISTRATION NO/DATE: 2202115.00.00 20200818 |
| 2968172 | SPC/GB20/043 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: CALCIFEDIOL, AND/OR A SALT OR HYDRATE THEREOF, IN PARTICULAR CALCIFEDIOL MONOHYDRATE; REGISTERED: UK PL 50784/0005-0001 20200721 |
| 2481400 | C02481400/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: CALCIFEDIOL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67614 22.12.2020 |
| 2481400 | 122020000079 | Germany | ⤷ Sign Up | PRODUCT NAME: CALCIFEDIOL UND/ODER PHARMAZEUTISCH AKZEPTABLE SALZE UND HYDRATE DAVON, BEVORZUGT CALCIFEDIOLMONOHYDRAT; NAT. REGISTRATION NO/DATE: 2202115.00.00 20200818; FIRST REGISTRATION: VEREINIGTES KOENIGREICH GROSSBRITANNIEN UND NORDIRLAND PL 50784/0005 - 0001 20200721 |
| 2481400 | CA 2020 00059 | Denmark | ⤷ Sign Up | PRODUCT NAME: CALCIFEDIOL; NAT. REG. NO/DATE: 62564 20200910; FIRST REG. NO/DATE: UK PL 50784/0005-0001 20200721 |
| 2481400 | 301085 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CALCIFEDIOL IN IEDERE VORM ZOALS BESCHERMD DOOR HET BASISOCTROOI; NATIONAL REGISTRATION NO/DATE: 124799 20200922; FIRST REGISTRATION: DE 2202115.00.00 20200819 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
